Enanta Pharmaceuticals Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Enanta Pharmaceuticals stock.
View analyst ratings for Enanta Pharmaceuticals or view top-rated stocks.

7 Wall Street research analysts have issued twelve-month target prices for Enanta Pharmaceuticals' shares. Their ENTA stock forecasts range from $44.00 to $103.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $73.43 in the next year. This suggests a possible upside of 48.0% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $74.78 on January 1st, 2022. Since then, ENTA stock has decreased by 33.6% and is now trading at $49.63.
View the best growth stocks for 2022 here.

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Enanta Pharmaceuticals.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings results on Monday, May, 9th. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.43) by $0.20. The biotechnology company earned $18.72 million during the quarter, compared to the consensus estimate of $20.40 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 28.80% and a negative net margin of 122.68%. During the same period last year, the company earned ($1.09) EPS.
View Enanta Pharmaceuticals' earnings history.

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Enanta Pharmaceuticals include Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT) and Blueprint Medicines (BPMC).
View all of ENTA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $49.63.

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $1.03 billion and generates $97.07 million in revenue each year. The biotechnology company earns $-79 million in net income (profit) each year or ($5.52) on an earnings per share basis.

Enanta Pharmaceuticals employs 155 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for Enanta Pharmaceuticals is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530.